Want to join the conversation?
$FISV raised its full year 2015 adjusted earnings guidance to $3.84-3.87 per share from its previous range of $3.73-3.83 per share representing a growth of 14-15% over $3.37 in 2014 and forecast full year 2015 internal revenue growth of 5%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.